Skip to main content
. Author manuscript; available in PMC: 2022 Feb 7.
Published in final edited form as: Gynecol Oncol. 2020 Oct 31;160(1):302–311. doi: 10.1016/j.ygyno.2020.10.010

Fig. 3.

Fig. 3.

Isobolograms of Mebendazole and PRIMA-1MET Combinations. Isobolograms of Mebendazole and PRIMA-1MET in a different p53 mutant ovarian cancer cells (MES-OV (R282 p53), ES2 (S241F p53), SKOV3 (R273H p53), SKOV3 (R248W p53), SKOV3 (p53 Null) and A2780 (WT)). Dose A: Mebendazole, Dose B: PRIMA-1MET.